TABLE 1.

Compilation of a Large Group²² of Publications Documenting Clinical Data of Keratoconus Treatment With Combined Customized Surface Ablation and Corneal Cross-linking, Some With Very Long-Term Follow-Up

Reference	Authors	Year	Protocol	Study Design	Cases	Follow-Up	UDVA	CDVA	SE	Keratometry Change	Complications
3	Wong JJ, et al	2006	Topo-PRK + CXL sequential	Case series	7	12 m	20/100–20/30	20/50–20/22	2.14 D	Kmax reduced 3 D	None
4	Kanellopoulos AJ, et al	2007	Topo-PRK + CXL sequential	Case report	1	18 m	20/100–20/20	20/50–20/15	5.25 D	Steep K reduced 5.5 D	None
6	Ewald M, et al	2008	Topo-PRK + CXL	Case series	45	19 m	20/400–20/100	27/32 >2.25 logMAR	6.4 D	53 D to 44 D (9 D)	1 case PK
7	Kanellopoulos AJ,	2009	Topo-PRK + CXL	Comp. Case series	198	36 m	0.96–0.3	0.39–0.16	3.2 D	3.5 D flatten	2 cases haze
13	Kymionis GD, et al	2009	Topo-PRK + CXL	Case series	23	24–48 m	Improved 0.38	Improved 0.1	NR	3.4 D flatten	None
14	Stojanovic A et al	2010	Topo-PRK + CXL	Case series	12	12 m	20/1000–20/125	20/57–20/35	NR	3.62 D flatten	None
15	Lin DT, et al	2012	Topo-PRK + CXL	Case series	66	6 m	58% 20/40 or better	92% 20/40 or better	NR	NR	None
10	Kanellopoulos AJ et al	2014	Topo-PRK + CXL	Case series	231	36 m	0.38	0.2	NR	46.56–44.44	None
15	Kapasi et al	2012	Topo-PRK + CXL	Case series	17	1 m	0.33 lines better	Not reported	NR	NR	None
15	Tuwairqi WS, et al	2012	Topo-PRK + CXL	Case series	22	12 m	Improved	Improved	NR	Reduced	15
15	Alessio et al	2013	Topo-PRK + CXL	Case series	17	24 m	0.44	0.003	NR	2.07 flatten	NR
9	Kanellopoulos AJ, et al	2011	Topo-PRK + CXL	Case series	32	27 m	27/32 >2.25 logMAR	27/32 >2.25 logMAR	2.3 D	3.34 D flatten	None
15	Sakla H, et al	2016	Topo-PRK + CXL	Case series	85	12 m	0.86–0.46 improved	0.41–0.11 improved	1.71 D	Steep 48.1–46.05 D	None
13	Grenzelos MA et al	2017	Topo-PRK + CXL	Case series	55	12 m	0.59 improved	0.12 improved	NR	Steep K reduced 4.03 D	7.3% haze
15	Ohana	2018	Topo-PRK + CXL	Case series	98	25.3 m	1.23 logMAR improved	Not improved	NR	4.03 D flatten	5% haze
15	Iqbal M et al	2019	Topo-PRK + CXL	Case series	67	24 m	0.68 logMAR improved	NR	2.31 D	Mean K reduced 0.36 D	1 keratitis
15	Gore et al	2018	Wavefront-PRK + CXL	Case series	47	24 m	NR	0.13 logMAR improved	NR	Steep K reduced 5.4 D	NR
15	Nattis et al	2018	Topo-PRK + CXL sequential	Case series	56	6 m	NR	93% 20/40 or better	NR	No change	NR
13	Kymionis GD, et al	2012	PTK + CXL	Case series	19	12 m	0.36 improved	0.12 improved	NR	steep K: reduced 2.07 D	NR
15	Assaf A, et al	2015	Topo-PRK + CXL sequential	Case series	22	10.9 m	0.87 improved	0.34	NR	meanK reduced 1.75 D	None
16	Kanellopoulos AJ,	2019	Topo-PRK + CXL	Case series	144	128 m	0.19–0.55	0.59–0.81		Kmax reduced 7.6 D	3.5% hyperopic shift
11	Kanellopoulos AJ, et al	2019	Topo-PRK + CXL pediatric	Case series	39	48 m	0.51–0.65	0.71–0.81	NR	Kmax reduced 8.7 D	2 late haze
15	Kaiserman I, et al	2019	PTK + CXL	Case report	20	27.5 m	0.95–0.22	0.24–0.13	NR	Kmax 48.18–45.97	None

The impressive similarities in improvement of UDVA, CDVA, and corneal flattening underline the efficacy in ectasia stabilization along with the improvement of visual function.